Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Many inflammatory bowel disease (IBD) patients exhibit resistance to conventional medical therapies.
• Tofacitinib, a Janus kinase inhibitor, is approved for ulcerative colitis (UC) treatment.
• This study evaluates tofacitinib's efficacy in moderate-to-severe IBD patients.

Purpose of the Study:

• To assess the effectiveness and safety of tofacitinib in patients with moderate-to-severe IBD.
• To evaluate clinical response, remission rates, and adverse events associated with tofacitinib treatment.
• To determine tofacitinib's utility in anti-TNF-resistant IBD cases.

Main Methods:

• Retrospective, observational study design.
• Oral administration of tofacitinib (5 mg or 10 mg twice daily) to IBD patients.
• Assessment of clinical response, remission, and adverse events at 8, 26, and 52 weeks.

Main Results:

• 36% of patients achieved clinical response and 33% clinical remission at 8 weeks.
• 27% of patients achieved steroid-free remission by 1 year.
• Adverse events included 12 episodes of systemic infections and 1 herpes zoster infection.

Conclusions:

• Tofacitinib demonstrates efficacy in inducing clinical response in 69% of patients with anti-TNF-resistant IBD.
• Approximately 27% of patients achieved steroid-free remission within one year.
• Tofacitinib represents a viable therapeutic option for challenging moderate-to-severe IBD populations.